drugset / Trial / NCT07033299
The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
Phase 1
Not yet recruiting
12 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A clinical study exploring the safety, efficacy, and cellular metabolic kinetics of universal CD19/20 CAR-T cell injection in anti neutrophil cytoplasmic antibody associated vasculitis. This study is a single arm, open label, exploratory dose escalation clinical trial aimed at evaluating the safety, efficacy, and cellular metabolic dynamics of CT1192 cells in patients with ANCA associated vasculitis.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | 3e+08 cells | — |
| Subject | Axicabtagene Ciloleucel | Cell therapy | 4.5e+08 cells | — |
| Subject | Axicabtagene Ciloleucel | Cell therapy | 6e+08 cells | — |